251 related articles for article (PubMed ID: 32727149)
1. Drug Repositioning of the α
Florent R; Poulain L; N'Diaye M
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32727149
[TBL] [Abstract][Full Text] [Related]
2. Reduction of prostate cancer incidence by naftopidil, an α1 -adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
Yamada D; Nishimatsu H; Kumano S; Hirano Y; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Kume H; Homma Y
Int J Urol; 2013 Dec; 20(12):1220-7. PubMed ID: 23600973
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
Matsukawa Y; Funahashi Y; Takai S; Majima T; Ogawa T; Narita H; Kato M; Gotoh M
J Urol; 2017 Feb; 197(2):452-458. PubMed ID: 27615436
[TBL] [Abstract][Full Text] [Related]
4. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.
Kojima Y; Sasaki S; Kubota Y; Hayase M; Hayashi Y; Shinoura H; Tsujimoto G; Kohri K
J Urol; 2008 Mar; 179(3):1040-6. PubMed ID: 18206918
[TBL] [Abstract][Full Text] [Related]
5. Editorial comment from Dr Murtola to reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
Murtola TJ
Int J Urol; 2013 Dec; 20(12):1227-8. PubMed ID: 23600459
[No Abstract] [Full Text] [Related]
6. Editorial comment from Dr Chen to reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
Chen IJ
Int J Urol; 2013 Dec; 20(12):1227. PubMed ID: 23600404
[No Abstract] [Full Text] [Related]
7. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical evaluation of naftopidil enantiomers: Rat functional assays in vitro and estrogen/androgen induced rat benign prostatic hyperplasia model in vivo.
Huang JJ; Cai Y; Yi YZ; Huang MY; Zhu L; He F; Liu XW; Huang BY; Yuan M
Eur J Pharmacol; 2016 Nov; 791():473-481. PubMed ID: 27615445
[TBL] [Abstract][Full Text] [Related]
9. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
[TBL] [Abstract][Full Text] [Related]
10. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma.
Hori Y; Ishii K; Kanda H; Iwamoto Y; Nishikawa K; Soga N; Kise H; Arima K; Sugimura Y
Cancer Prev Res (Phila); 2011 Jan; 4(1):87-96. PubMed ID: 21205739
[TBL] [Abstract][Full Text] [Related]
11. Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Masumori N; Hashimoto J; Itoh N; Tsukamoto T;
Scand J Urol Nephrol; 2007; 41(5):422-9. PubMed ID: 17853040
[TBL] [Abstract][Full Text] [Related]
12. Influence of Naftopidil on Plasma Monoamine Levels and Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
Kadekawa K; Sugaya K; Mukoyama H; Sakumoto M; Shimabukuro H; Shimabukuro S; Matayoshi Y; Onaga T; Ashitomi K; Nishijima S
Low Urin Tract Symptoms; 2016 May; 8(2):100-5. PubMed ID: 27111621
[TBL] [Abstract][Full Text] [Related]
13. Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib.
Florent R; Weiswald LB; Lambert B; Brotin E; Abeilard E; Louis MH; Babin G; Poulain L; N'Diaye M
Cell Death Dis; 2020 May; 11(5):380. PubMed ID: 32424251
[TBL] [Abstract][Full Text] [Related]
14. Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest.
Kanda H; Ishii K; Ogura Y; Imamura T; Kanai M; Arima K; Sugimura Y
Int J Cancer; 2008 Jan; 122(2):444-51. PubMed ID: 17918159
[TBL] [Abstract][Full Text] [Related]
15. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
Maruyama O; Kawachi Y; Hanazawa K; Koizumi K; Yamashita R; Sugimura S; Honda S; Sugiyama Y; Saitoh T; Noto K
Int J Urol; 2006 Oct; 13(10):1280-5. PubMed ID: 17010005
[TBL] [Abstract][Full Text] [Related]
16. Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients.
Kojima Y; Sasaki S; Shinoura H; Hayase M; Kubota Y; Hayashi Y; Tsujimoto G; Kohri K
Prostate; 2007 Sep; 67(12):1285-92. PubMed ID: 17626248
[TBL] [Abstract][Full Text] [Related]
17. Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.
Kojima Y; Sasaki S; Oda N; Koshimizu TA; Hayashi Y; Kiniwa M; Tsujimoto G; Kohri K
Prostate; 2009 Oct; 69(14):1521-8. PubMed ID: 19544328
[TBL] [Abstract][Full Text] [Related]
18. Naftopidil for the treatment of benign prostate hyperplasia: a systematic review.
Castiglione F; Benigni F; Briganti A; Salonia A; Villa L; Nini A; Di Trapani E; Capitanio U; Hedlund P; Montorsi F
Curr Med Res Opin; 2014 Apr; 30(4):719-32. PubMed ID: 24188134
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia.
Funahashi Y; Hattori R; Matsukawa Y; Komatsu T; Sassa N; Gotoh M
World J Urol; 2011 Apr; 29(2):225-31. PubMed ID: 20309563
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells.
Iwamoto Y; Ishii K; Kanda H; Kato M; Miki M; Kajiwara S; Arima K; Shiraishi T; Sugimura Y
J Cancer Res Clin Oncol; 2017 Jun; 143(6):933-939. PubMed ID: 28243746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
